Review

Cell and Tissue Research

, Volume 318, Issue 1, pp 261-273

First online:

Stem cell therapy for Parkinson’s disease: where do we stand?

  • Laurent RoybonAffiliated withSection for Neuronal Survival, Wallenberg Neuroscience Center, Lund University Email author 
  • , Nicolaj S. ChristophersenAffiliated withSection for Neuronal Survival, Wallenberg Neuroscience Center, Lund University
  • , Patrik BrundinAffiliated withSection for Neuronal Survival, Wallenberg Neuroscience Center, Lund University
  • , Jia-Yi LiAffiliated withSection for Neuronal Survival, Wallenberg Neuroscience Center, Lund University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

A major neuropathological feature of Parkinson’s disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.

Keywords

Parkinson’s disease Neural grafting Embryonic stem cells Somatic adult stem cells